NHD Global
Cosmetic & Skin · Copper tripeptide research
Product specifications & quotation
GHK-Cu is a small copper-binding peptide studied in skin and tissue-repair research. Cell experiments have examined collagen production; collagen is a protein that gives tissues structure. These laboratory findings help explain interest in the compound, but human evidence is limited and not uniformly positive. This page separates cell, animal and human findings, then lists catalog identity and research variants. Ask for the actual supplied form and available records before comparing quotations.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Collagen helps support the structure of skin and other tissues. A published fibroblast-culture experiment found that GHK-Cu stimulated collagen synthesis. This explains the interest in skin research, while remaining a cell-level result. PMID 3169264.
An experimental finding, not a measured benefit of an NHD supplied lot.
Read the primary studyAmong 13 completers, blinded and computer assessments found no significant GHK-Cu advantage for erythema, wrinkles or overall skin quality.
The questionnaire favored perceived skin quality at p=0.04; exploratory given the small sample.
Read the primary studyFDA flags potential aggregation, peptide-impurity and immunogenicity concerns for injectable GHK-Cu.
A topical study cannot close an injectable-route safety gap.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
50 mg nominal per vial · 10 vials per pack. Confirm supplied form, mass basis and lot release specifications before ordering.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
100 mg nominal per vial · 10 vials per pack. Confirm supplied form, mass basis and lot release specifications before ordering.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.
View primary recordU.S. FDA injectable GHK-Cu summary.
View primary recordPrimary rat wound-chamber study; this is preclinical repair evidence. PMID 8227353.
View primary recordThird-party publications selected for direct relevance.
Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
The clearest effect is increased collagen production in cultured fibroblasts. In rat wound chambers, more collagen and connective tissue accumulated. In people, a small trial of topical GHK-Cu after laser resurfacing found no objective skin differences; only a questionnaire favored perceived skin quality. These are model-specific findings, not proven benefits from a specific supplied lot.
The FDA has flagged potential concerns for injectable GHK-Cu used in compounding, including aggregation, peptide impurities, and immune reactions. These are route-specific issues. A topical study cannot resolve injectable safety questions, nor can laboratory collagen data. Route, formulation, and salt form all affect what evidence applies, so topical and injectable research should be evaluated separately.
CU50 lists 50 mg per vial and CU100 lists 100 mg per vial. Both are 10-vial packs. These are nominal catalogue sizes; confirm the supplied form, mass basis and release specifications before ordering.
A catalogue listing is not a stock confirmation. Tell us the vial size, number of packs and destination so we can confirm availability and quotation details.
Ask which documents are available for the selected variant and lot. A COA, specification sheet or method summary is not guaranteed by this listing; availability and scope must be confirmed before ordering.
Include the product name, catalogue code, vial size, number of packs, research purpose, destination and required documents. Mention any requirements for supplied form, purity or peptide content so they can be assessed separately.
The listed mg per vial is a nominal catalogue size. It does not establish measured peptide content or purity. Confirm what the mass refers to and which measurements are available for the selected lot.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
In the study with 13 completers, objective assessments found no significant group differences. One patient questionnaire favoured perceived skin quality at p=0.04. These topical findings do not validate injectable use.
GHK and the copper complex are different descriptions of material. A paper may also use a particular preparation or medium. State the intended research material clearly and ask which identity fields and documents apply to the selected variant.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
The most directly relevant randomized topical GHK-Cu study was small: 13 patients completed it. Objective assessments did not find significant differences in erythema resolution,…
Updated October 1, 2026
Route is not a footnote in GHK-Cu evidence. A topical skin-care study and an injectable compounded preparation have different exposure, sterility, aggregation and safety…
Updated October 1, 2026
GHK and GHK-Cu have similar names, but they are different descriptions of material. The study discussed here examined GHK in lung fibroblasts, cells involved…
Updated October 9, 2026
A simple introduction to peptide pricing: why sequence, purity, quantity, packaging and testing can change a quote, and what to ask before ordering.
Updated October 9, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CU50 · 50 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
